Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: J Immunol. 2016 Nov 14;197(12):4663–4673. doi: 10.4049/jimmunol.1601484

Figure 2. Immunization of m2F5 DKI mice with MPER peptide-liposomes.

Figure 2

(A) Plasma antibody binding of SP62 and KYNU at pre-immunization (bleed 0) and after 7 immunizations (bleeds 1-7) with MPER peptide-liposomes formulated with Alum, GLA or GLA + Alum adjuvants measured by ELISA. Binding for each individual animal displayed, bar indicates group mean. (B) Plot of plasma antibody binding titers to SP62 and KYNU for each mouse in all adjuvant groups at bleed 6. Axis are Log AUC in ELISA. Spearman correlation shown (r = 0.98; P < 0.0001). (C) Plasma antibody HIV neutralization of MN virus measured in the TZM-bl neutralization assay at bleed 6 for mice immunized with MPER peptide-liposomes formulated with Alum, GLA or GLA + Alum adjuvants. (D) KYNU enzymatic assay indicating the percent change in KYNU activity for control antibodies (left panel; h = human antibody, Rh = rhesus macaque antibody) and mice from all three adjuvant groups pre and post 5th immunization (right three panels). Binding for each individual mouse displayed.